Abstract
Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-κB is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-κB in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-κB was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-κB. In mesenchymal cells from MM-patients NF-κB was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-κB activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-κB localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM. © 2010 Elsevier Ltd.
Lingua originale | English |
---|---|
pagine (da-a) | 52-60 |
Numero di pagine | 9 |
Rivista | Leukemia Research |
Volume | 35 |
DOI | |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Antineoplastic Agents
- Blotting, Western
- Boronic Acids
- Bortezomib
- Cancer Research
- Cell Line, Tumor
- Flow Cytometry
- Hematology
- Humans
- Immunohistochemistry
- Mesenchymal cells
- Mesoderm
- Multiple Myeloma
- Multiple myeloma
- NF-kappa B
- NF-κB
- Oncology
- Plasma Cells
- Pyrazines